Zaki Sellam is an experienced C-level biotech executive, with over two decades of experience and leadership in cancer/immunology drug discovery, translational medicine, clinical development, biotech startups, and fostering strategic alliances between prominent pharmaceutical companies and academic institutions. Mr. Sellam has raised approximately $100 million in equity financing in this sector. In addition to his role as CEO of Landmark BioVentures AG, he also serves as Executive Chairman to each of LBV nexus companies.

Previously, Mr. Sellam was Founder and CEO of Avicenna Oncology GmbH, an Antibody Drug Conjugate start up located in Basel (2014-2019). Mr. Sellam also advises start-up companies, (including Iome Bio, Harvard spin off), Tech Transfer Accelerators and pharma companies (including OM Pharma) through his strategic consulting firm ESN Life Sciences GmbH (2011-present).

Mr. Sellam earned an MS in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France (2002) and an MBA from the Institute of Business Administration in Poitiers, France (2007).

Gary Brandam is a biotech entrepreneur and experienced C-level biotech executive with over 15 years of experience in drug development, product launch, corporate strategy, and startup company build-up in the areas of oncology, rare diseases, and gene therapies. In addition to his role as COO of Landmark BioVentures AG, he also serves as advisor to each of LBV nexus companies and CEO of both Elikya Therapeutics and Massalia Therapeutics.

Previously, he was a manager at Blue Matter Consulting (2015-2023) where he advised several global pharmaceutical companies launching their oncology and/or rare disease products in the US, Europe, and other markets worldwide. Mr. Brandam served as project lead within Avicenna Oncology GmbH, an Antibody Drug Conjugate start-up located in Basel (2015-2017).

Mr. Brandam earned an MS in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France (2011).

Josh Pan is a versatile biotech executive with experience across start-ups, high growth businesses, and IPOs. He co-founded 2 companies in 2024, Numiera Therapeutics and X-tosis, focusing on glioblastoma and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Dr. Pan is Member and Partner of Bellevue Capital Management supporting corporate strategy and execution since March 2015; he also serves as Venture Partner for OSR Holdings, Inc. (Nasdaq: OSRH) evaluating and advising on corporate ventures and drug development strategies. He is founder and Principal of S-Phase Ventures, LLC, a boutique strategy, operations and business development consultancy for start-ups, venture funds, and non-profit organizations since 2015. In addition to his role as CBO of Landmark BioVentures AG, he also serves as advisor to LBV nexus companies with a specific focus on Roca Therapeutics and SPIMA Therapeutics.

Previously, Dr. Pan served in roles of increasing responsibility at Athira Pharma, Inc. (Nasdaq: ATHA) from 2015 to July 2023 supporting business development, corporate development, corporate communications, medical affairs, product commercialization and corporate financing from 2015 through to its IPO in September 2020; his latest appointment with Athira was Vice President of Corporate Development and External Affairs. He has also held appointments as Associate and later, Interim Chief Operating Officer for W Fund, a Seattle, Washington-based early-stage venture fund from 2013-2015.

Dr. Pan earned a BS in Chemistry from Oregon State University (2004), and an MBA (2011) and PhD in Molecular and Cellular Biology (2012), both from the University of Washington.

Mehdi Chelbi is an entrepreneur in biotech and healthcare with over 20 years of experience in drug discovery, preclinical and clinical development, regulatory affairs and post-marketed studies. Mr. Chelbi co-founded several startup biotech and life sciences companies where he held C-Level and/or Board Member positions. In addition to his role as CVO of Landmark BioVentures AG, he also serves as advisor to each of LBV nexus companies and is co-founder and Board Member of Carla Biotherapeutics.

Mr. Chelbi is Co-Founder and Chief Executive Officer of BiPER Therapeutics, a biotech company developing first-in-class therapeutics to treat cancers with high unmet medical needs since July 2021. He is also Board Member and Co-Founder of G.CLIPS, a biotech company focused on the discovery and development of drugs and antibodies targeting membrane proteins.

Prior to founding BiPER Therapeutics and G.CLIPS Biotech, Mr. Chelbi was Director and Member of Executive Committee of 4Clinics (2010-2020), an international clinical research organization, where he successfully managed its global expansion, including the development of the European headquarters and the opening of 2 offices in North America. At 4Clinics, Mr. Chelbi was responsible for the company’s global development and overall business strategy supporting 300+ Phase 1 to Phase IV clinical trials for its portfolio of 150+ pharma, biotech and medtech clients worldwide. Mr. Chelbi started his career in business development at Idealp-Pharma (2004-2010), a company specializing in medicinal chemistry, drug discovery and preclinical development. He supported the drug discovery and development programs of 100+ pharma and biotech companies in different indications including cardio-vascular disease, infectious disease, neurology and oncology.

Mr. Chelbi earned an MSc in Biology from Université Sciences et Techniques Lille 1 (2003).

Jacques Bauer is an experienced C-level biotech executive with over 35 years of experience and leadership in the pharmaceutical industry. He has held positions including Head of Research, Head of Research & Development and Head of Intellectual Property at several companies including Laboratoires OM (1985-1995), OM Pharma (1995-2009), Galenica (2009-2012), and Vifor Pharma (2012-2020).

Dr. Bauer is Founder and CEO of Inventuri Development (2021-present), a consultancy company advising on intellectual property and technical support issues in the life sciences and medicinal chemistry industries, located in Saint-Prex, Switzerland. In addition to his role as CDSO of Landmark BioVentures AG, he also serves as Chief Scientific Officer at Elikya Therapeutics and Duhn Therapeutics.

His professional achievements in medicinal chemistry include the successful development of small innovative first in class synthetic drugs from discovery to clinical level, and leading the development and industrial scaling-up of biologicals to market. Dr. Bauer’s project management experience encompasses matters related to intellectual property, chemistry, preclinical sciences, pharmacokinetics and early clinical stages in cancer and immunology.

Dr. Bauer earned an MS in Biology from University of Lausanne (1980) and a PhD in Medicinal and Pharmaceutical Chemistry from University of Lausanne (2001). Additionally, Dr. Bauer received intellectual property and industrial property law training from Centre Paul Roubier (2006).

Samson Fung is an experienced clinical MD and C-level biotech executive, with over 30 years of experience and leadership in oncology/immunology, clinical development, translational medicine, regulatory affairs (FDA and EMA) and advising biotechs in startup/advanced stages. Dr. Fung is Founder/Chief Medical Officer of Susavox Investments GmbH (2018-present) and was previously Founder/Chief Executive Officer of Volvox Therapeutics GmbH (2013-2018); both are oncology biotech startup companies based in Munich and Cambridge, Massachusetts. As CMO of Landmark BioVentures AG, he provides clinical development and clinical strategy leadership and trial oversight to each of LBV nexus companies. 

Dr. Fung is Chief Medical Officer/Board Member at Molecure SA, Warsaw, Poland (WSE: MOC) (2022-present). Since 2008, Dr. Fung has advised companies such as Micromet, Roche, Novartis, Pharmacia/Pfizer, Novo Nordisk, AstraZeneca, Iome (affiliated with Harvard Medical School), and organizations such as Inhatarget SA in Belgium, BioM (Munich), and Simbec-Orion (based in UK and France), where he is also Member of the Scientific Advisory Board. He has been involved in more than 20 due diligence projects leading to in-/out-licensing of compounds in early and late-stage development.

Dr. Fung earned an MD from the University of Freiburg, Germany (1984) and Board Certification in internal medicine with sub-specialization in oncology and hematology (1992). He spent more than 8 years in academic teaching hospitals practicing general internal medicine, gastroenterology, nephrology and hemato-and medical oncology.